On The Horizon: New Oral Therapies for Type 2 Diabetes Mellitus
Journal Title: International Journal of Diabetology & Vascular Disease Research (IJDVR) - Year 2013, Vol 1, Issue 3
Abstract
The first documented case of diabetes mellitus occurred earlier than 4000 BC. Since then, many of the brightest minds in medicine have dedicated their time and effort toward developing treatments that can reverse the course of this deadly disease. As our understanding of the pathogenesis of diabetes increases, so does the availability of treatment options. The fight against diabetes once only had metformin and sulfonylureas as the cornerstone of oral treatment, but now, multiple classes have been added to this armamentarium including thiazolidenediones (TZDs) and dipeptidyl peptidase IV (DDP IV) inhibitors. These therapies provide reasonable durable glycemic control but are unable to arrest the natural progression of diabetes or the eventual need for insulin. By utilizing our growing knowledge on the pathogenesis of diabetes, a number of new therapeutic agents are in development to overcome the shortcomings of current therapies. Promising options on the horizon include sodium-coupled glucose cotransport 2 (SGLT2) inhibitors, Ranolazine, Salicylates, second generation Peroxisome proliferator ac-tivator receptor agonists (PPARs), and 11-beta hydroxysteroid dehydrogenase type 1 inhibitors (11-beta HSD1 inhibitors). Various molecules, including some enzymes, are also in development particularly to address beta cell preservation and its sensitivity to glucose, while minimizing hypoglycemia. Most of these new classes of drugs consist of daily administration, simplifying the regimen for patients and likely increasing medication compliance. This article reviews the new agents that are advancing through clinical trials, their mechanism of actions, glucose lowering effect and possible side effects and limitations
Authors and Affiliations
Intekhab Ahmed
Keywords
Related Articles
- EP ID EP197782
- DOI 10.19070/2328-353X-130004
- Views 153
- Downloads 0
Eating Timing and Diabetes
Eating Timing and Diabetes
Total Adiponectin and Risk of Symptomatic Lower Extremity Peripheral Vascular Disease in Type 2 Diabetes Mellitus
Objective: Adiponectin is an adipocyte-derived protein that has gained considerable research interest because of its pleiotropic effects on insulin sensitivity, atherosclerosis and inflammation. Lower concentrations of a...
Genetic Determinants of Type 2 Diabetes in Asians
Type 2 diabetes (T2D) has become a major health problem throughout the world and the epidemic is particularly severe in Asian countries. Compared with European populations, Asians tend to develop diabetes at a younger ag...
A Non-Invasive Glucose Estimation in Saliva Samples by using Pre Column Derivatised RP-HPLC
Diagnostic devices available in the market to measure blood glucose level which requires blood as diagnostic body fluid. Hence, necessity arises to find some non-invasive diagnostic mean to measure body glucose level fre...
The Risk of Subsequent Amputation Following An Initial Lower Extremity Amputation: A Systematic Review
Purpose: Quantifying subsequent amputation incidence after an initial amputation, whether affecting the ipsilateral or contralateral lower extremity, may enhance decision-making regarding risk reduction. This systematic...